<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651871</url>
  </required_header>
  <id_info>
    <org_study_id>1210D1526</org_study_id>
    <nct_id>NCT01651871</nct_id>
  </id_info>
  <brief_title>Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis</brief_title>
  <official_title>A Phase 2, Multicenter, Parallel-Group, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Combination Study Of S-555739 And Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <brief_summary>
    <textblock>
      The primary objective of the study was to examine the efficacy and safety of
      S-555739/cetirizine HCl compared with the individual components and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average morning/evening (AM/PM) reflective Total Nasal Symptom Score (rTNSS)</measure>
    <time_frame>Change from baseline through the 2-week treatment period (Day 2 through Day 15)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>From Screening period to Week 6 (Follow-up)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in average AM/PM instantaneous Total Nasal Symptom Score (iTNSS)</measure>
    <time_frame>Change from baseline through the 2-week treatment period (Day 2 through Day 15)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average AM/PM Total Ocular Symptom Score</measure>
    <time_frame>Change from baseline through the 2-week treatment period (Day 2 through Day 15)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality of Life</measure>
    <time_frame>Change from Week 3 to Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of vital signs</measure>
    <time_frame>At Week 1 (Screening), Week 2, Week 3, Week 4, and Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical laboratory parameters</measure>
    <time_frame>At Week 1 (Screening), Week 4, Week 5, and Week 6 (Follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of electrocardiogram (ECG) findings</measure>
    <time_frame>At Week 1 (Screening) and Week 5</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">779</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-555739 Dose 1</intervention_name>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_label>Treatment Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-555739 Dose 2</intervention_name>
    <arm_group_label>Treatment Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine HCl Dose 1</intervention_name>
    <arm_group_label>Treatment Group 4</arm_group_label>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_label>Treatment Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-555739 placebo</intervention_name>
    <arm_group_label>Treatment Group 4</arm_group_label>
    <arm_group_label>Treatment Group 5</arm_group_label>
    <arm_group_label>Treatment Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine HCl placebo</intervention_name>
    <arm_group_label>Treatment Group 3</arm_group_label>
    <arm_group_label>Treatment Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History and diagnosis of seasonal allergic rhinitis by skin prick test

          -  Have nasal symptom scores as defined by the study protocol

          -  Able to comply with study procedures

        Exclusion Criteria:

          -  Any nasal disease or abnormality, active respiratory tract infections within the past
             2 weeks, or recent nasal surgery or sinus surgery at Screening

          -  Use of any prohibited concomitant drugs or therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <disposition_first_submitted>April 26, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 27, 2018</disposition_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Agents, anti allergic</keyword>
  <keyword>Nasal congestion</keyword>
  <keyword>Sneezing</keyword>
  <keyword>Nasal discharge</keyword>
  <keyword>D prostanoid (DP) receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

